Pharmacologic treatment of chronic obstructive pulmonary disease

Past, present, and future

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Pharmacologic treatment of chronic obstructive pulmonary disease (COPD) has evolved considerably during the past several decades. Initial treatment of the disease was accomplished primarily through antibiotics, mucolytic agents, and nonselective sympathomimetic agents. Up-to-date treatment guidelines stratified according to strength of evidence are published in the National Heart, Lung, and Blood Institute-World Health Organization workshop report on the Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Current drug therapy for stable COPD focuses primarily on bronchodilation through inhaled β2-agonists and anticholinergic agents, immunization, and elimination of smoking as a risk factor. Although many pharmacologic agents are available to treat COPD, no drug has demonstrated effectiveness in halting progression of the disease. Rather, the goal of drug therapy at this time is to maintain control of symptoms and prevent COPD exacerbations. Compared with asthma, research into treatment for COPD has been minimal. However, a long-acting anticholinergic agent, tiotropium, has received approval status by the United States Food and Drug Administration. The drug has been shown to improve spirometric parameters, quality of life, and utilization of health care resources. In addition, several new targets for the treatment of COPD are being studied, and a few agents, including some that theoretically may slow functional decline in patients with COPD, are in development.

Original languageEnglish
Pages (from-to)1300-1315
Number of pages16
JournalPharmacotherapy
Volume23
Issue number10 II
DOIs
StatePublished - Oct 1 2003

Fingerprint

Chronic Obstructive Pulmonary Disease
Cholinergic Antagonists
Therapeutics
Disease Progression
Expectorants
National Heart, Lung, and Blood Institute (U.S.)
Drug Therapy
Sympathomimetics
Health Resources
United States Food and Drug Administration
Pharmaceutical Preparations
Immunization
Asthma
Smoking
Quality of Life
Guidelines
Anti-Bacterial Agents
Education
Research

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacologic treatment of chronic obstructive pulmonary disease : Past, present, and future. / Faulkner, Michele A.; Hilleman, Daniel E.

In: Pharmacotherapy, Vol. 23, No. 10 II, 01.10.2003, p. 1300-1315.

Research output: Contribution to journalReview article

@article{2d6fdec5a7fc4e81b201fcbd2cc581bf,
title = "Pharmacologic treatment of chronic obstructive pulmonary disease: Past, present, and future",
abstract = "Pharmacologic treatment of chronic obstructive pulmonary disease (COPD) has evolved considerably during the past several decades. Initial treatment of the disease was accomplished primarily through antibiotics, mucolytic agents, and nonselective sympathomimetic agents. Up-to-date treatment guidelines stratified according to strength of evidence are published in the National Heart, Lung, and Blood Institute-World Health Organization workshop report on the Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Current drug therapy for stable COPD focuses primarily on bronchodilation through inhaled β2-agonists and anticholinergic agents, immunization, and elimination of smoking as a risk factor. Although many pharmacologic agents are available to treat COPD, no drug has demonstrated effectiveness in halting progression of the disease. Rather, the goal of drug therapy at this time is to maintain control of symptoms and prevent COPD exacerbations. Compared with asthma, research into treatment for COPD has been minimal. However, a long-acting anticholinergic agent, tiotropium, has received approval status by the United States Food and Drug Administration. The drug has been shown to improve spirometric parameters, quality of life, and utilization of health care resources. In addition, several new targets for the treatment of COPD are being studied, and a few agents, including some that theoretically may slow functional decline in patients with COPD, are in development.",
author = "Faulkner, {Michele A.} and Hilleman, {Daniel E.}",
year = "2003",
month = "10",
day = "1",
doi = "10.1592/phco.23.12.1300.32699",
language = "English",
volume = "23",
pages = "1300--1315",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "10 II",

}

TY - JOUR

T1 - Pharmacologic treatment of chronic obstructive pulmonary disease

T2 - Past, present, and future

AU - Faulkner, Michele A.

AU - Hilleman, Daniel E.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Pharmacologic treatment of chronic obstructive pulmonary disease (COPD) has evolved considerably during the past several decades. Initial treatment of the disease was accomplished primarily through antibiotics, mucolytic agents, and nonselective sympathomimetic agents. Up-to-date treatment guidelines stratified according to strength of evidence are published in the National Heart, Lung, and Blood Institute-World Health Organization workshop report on the Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Current drug therapy for stable COPD focuses primarily on bronchodilation through inhaled β2-agonists and anticholinergic agents, immunization, and elimination of smoking as a risk factor. Although many pharmacologic agents are available to treat COPD, no drug has demonstrated effectiveness in halting progression of the disease. Rather, the goal of drug therapy at this time is to maintain control of symptoms and prevent COPD exacerbations. Compared with asthma, research into treatment for COPD has been minimal. However, a long-acting anticholinergic agent, tiotropium, has received approval status by the United States Food and Drug Administration. The drug has been shown to improve spirometric parameters, quality of life, and utilization of health care resources. In addition, several new targets for the treatment of COPD are being studied, and a few agents, including some that theoretically may slow functional decline in patients with COPD, are in development.

AB - Pharmacologic treatment of chronic obstructive pulmonary disease (COPD) has evolved considerably during the past several decades. Initial treatment of the disease was accomplished primarily through antibiotics, mucolytic agents, and nonselective sympathomimetic agents. Up-to-date treatment guidelines stratified according to strength of evidence are published in the National Heart, Lung, and Blood Institute-World Health Organization workshop report on the Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Current drug therapy for stable COPD focuses primarily on bronchodilation through inhaled β2-agonists and anticholinergic agents, immunization, and elimination of smoking as a risk factor. Although many pharmacologic agents are available to treat COPD, no drug has demonstrated effectiveness in halting progression of the disease. Rather, the goal of drug therapy at this time is to maintain control of symptoms and prevent COPD exacerbations. Compared with asthma, research into treatment for COPD has been minimal. However, a long-acting anticholinergic agent, tiotropium, has received approval status by the United States Food and Drug Administration. The drug has been shown to improve spirometric parameters, quality of life, and utilization of health care resources. In addition, several new targets for the treatment of COPD are being studied, and a few agents, including some that theoretically may slow functional decline in patients with COPD, are in development.

UR - http://www.scopus.com/inward/record.url?scp=0141754104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141754104&partnerID=8YFLogxK

U2 - 10.1592/phco.23.12.1300.32699

DO - 10.1592/phco.23.12.1300.32699

M3 - Review article

VL - 23

SP - 1300

EP - 1315

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 10 II

ER -